List of works - Nancy E Kemeny

(124)I-huA33 antibody PET of colorectal cancer.

scientific article

124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

scientific article

Actual 10-year survival after resection of colorectal liver metastases defines cure.

scientific article

Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents

scientific article

Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases

scientific article published in June 2008

Biliary Sclerosis after Hepatic Arterial Infusion Pump Chemotherapy for Patients with Colorectal Cancer Liver Metastasis: Incidence, Clinical Features, and Risk Factors

article

Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases

scientific article

Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer

article

Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer

scientific article published in June 2008

Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease

article

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection

scientific article

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

article

Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases

article

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

scientific article published on 21 July 2015

Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome

article

Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer

article

Phase I study of anticolon cancer humanized antibody A33.

scientific article published on April 2003

Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer

scientific article

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

scientific article published in December 2006

Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy

article

Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.

scientific article

Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.

scientific article

Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.

scientific article published on 23 May 2015

Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.

scientific article published on 25 March 2014

Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study

scientific article

Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer

scientific article

Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

scientific article published on 22 December 2015

List of works by Nancy E Kemeny

(124)I-huA33 antibody PET of colorectal cancer.

124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

Actual 10-year survival after resection of colorectal liver metastases defines cure.

Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents

Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases

Biliary Sclerosis after Hepatic Arterial Infusion Pump Chemotherapy for Patients with Colorectal Cancer Liver Metastasis: Incidence, Clinical Features, and Risk Factors

Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases

Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer

Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer

Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome

Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer

Phase I study of anticolon cancer humanized antibody A33.

Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy

Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.

Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.

Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.

Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.

Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study

Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer

Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.